Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.60
+0.31121.06%
Post-market: 29.660.0591+0.20%19:30 EDT
Volume:5K
Turnover:139.63K
Market Cap:55.35M
PE:- -
High:29.66
Open:29.08
Low:29.08
Close:29.29
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.44
T/O Rate:0.25%
Dividend:0.41
Dividend Rate:1.39%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Pfizer Sued by Florida Attorney General Over Alleged Deceptive Marketing Practices

MT Newswires Live
·
Oct 01

Florida sues Pfizer over COVID vaccine marketing

TIPRANKS
·
Oct 01

Florida Attorney General: Files Lawsuit Against Pfizer and Its CEO Albert Bourla

THOMSON REUTERS
·
Oct 01

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Kailera Therapeutics announces positive results from several presentations

TIPRANKS
·
Oct 01

Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites

Reuters
·
Oct 01

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

GlobeNewswire
·
Oct 01

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01